Rosetta Genomics $ROSG reported Q2 results on Tuesday. For the concluded quarter, revenue stood at $2.4mn, a 20% increase year-over-year. R&D expense rose 1.6% to $0.6mn. Selling, General, and Administrative expenses dropped 31.9% to $3.2mn. Net loss for the quarter was $3.4mn (21.4%).Loss Per Share: ($0.16) (+20.0%); Non-GAAP Loss per Share: ($0.15) (+55.9%); Quick Assets: $8.1M (-34.7%). The company did not provide any guidance.